1. What Is the Asthma Market?
The Asthma Market covers the medicines used to treat and control the allergic and non-allergic asthma across the mild, moderate, and severe disease severity spectrum. The market uses the inhaled corticosteroid backbone for the anti-inflammatory maintenance and the short-acting and long-acting beta2-agonists for the bronchodilation. The biologic anti-IL-5, anti-IL-4/IL-13, anti-IgE, and anti-TSLP antibodies treat the severe asthma that the high-dose ICS-LABA combination cannot adequately control. The uncontrolled airway inflammation creates the frequent exacerbations. Asthma management uses the step-up GINA Global Initiative for Asthma treatment ladder from the reliever-only Step 1 through the high-dose ICS-LABA plus biologic Step 5. Each step adds the pharmacological layer appropriate to the severity that the symptom control and the exacerbation frequency assessment identifies. The asthma market is expanded by tezepelumab that targets the upstream alarmin TSLP driving both eosinophilic and non-eosinophilic asthma phenotypes from the epithelial barrier dysfunction. The NAVIGATOR trial demonstrated the 70 percent exacerbation reduction across the blood eosinophil count spectrum that no other biologic achieves.
2. Asthma Market Size & Forecast
3. Emerging Technologies
- Tezepelumab Tezspire TSLP blockade NAVIGATOR Phase III demonstrated 70 percent exacerbation reduction versus placebo across all blood eosinophil count levels from less than 150 to greater than 300 cells per microlitre. The anti-TSLP is the first biologic that benefits the broad severe asthma population. The broad benefit extends beyond the eosinophil-selected subgroup that the anti-IL-5 benralizumab and mepolizumab require.
- Blood eosinophil count biomarker for anti-IL-5 biologic selection with mepolizumab and benralizumab shows the superior exacerbation reduction in the patients with blood eosinophil count above 150 to 300 cells per microlitre. The eosinophilic asthma phenotype represents the high-eosinophil population. The patients below the threshold receive less benefit from the eosinophil-targeting mechanism.
- Dupilumab Dupixent Type 2 asthma includes both the eosinophilic and the allergic phenotype with the blood eosinophil or the exhaled nitric oxide FeNO biomarker above the threshold. The drug demonstrated the 60 to 70 percent exacerbation reduction in the LIBERTY ASTHMA QUEST and TRAVERSE trials. The dual IL-4 and IL-13 blocker addresses both the eosinophilic and the allergic arm of the Type 2 inflammation. The Type 2 inflammation drives both phenotypes.
- ICS-formoterol as-needed Symbicort reliever therapy for the mild asthma in the SYGMA trials demonstrated the 64 percent exacerbation reduction versus the salbutamol reliever. The anti-inflammatory reliever concept replaced the bronchodilator-only reliever. The GINA 2021 guideline incorporated the anti-inflammatory reliever as the preferred Step 1 approach.
Such innovations are driving change across adjacent industries too. Discover more in our Copd Market.
4. Key Market Opportunity
A material opportunity in the Asthma market involves type 2 low asthma biologic expansion, where tezepelumab approval for severe asthma regardless of eosinophil level addresses a major unmet need in patients without type 2 high inflammation. Companies with type 2 low asthma biologic data capture this previously underserved population. Complementary growth involves ICS-LABA-LAMA triple inhaler expansion in moderate asthma. As type 2 low biologic adoption proceeds and triple inhaler use grows, the addressable opportunity is expanding from inhaler-and-type-2-high-biologic dominant treatment toward broader biologic and triple-inhaler asthma management.
5. Top Companies in the Asthma Market
The following organisations hold leading positions in the Asthma Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- GSK
- AstraZeneca
- Sanofi
- Regeneron
- Roche
- Novartis
- Teva Pharmaceutical
- Verona Pharma
- Mereo BioPharma
- Amgen
- Boehringer Ingelheim
- Merck
- Cipla
- Sun Pharma
- Lupin
- Viatris
- Vectura Group
- Glenmark Pharmaceuticals
6. Market Segmentation
The Asthma Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | ICSLABALAMALTRABiologic |
| By Severity | MildModerateSevere |
| By Phenotype | EosinophilicAllergicType 2 Low |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Asthma Market trajectory over the forecast period:
Tezepelumab TSLP Blockade NAVIGATOR 70 Percent Exacerbation Reduction Across All Blood Eosinophil Count Levels Including Less Than 150 Has Established the First Severe Asthma Biologic Benefiting the Full Spectrum Beyond the Eosinophil-Selected Subgroup That Anti-IL-5 Biologics Require.AstraZeneca and Amgen's tezepelumab demonstrated 70% exacerbation reduction in NAVIGATOR across patients with blood eosinophil counts below 150, 150-299, and above 300 cells/μL, establishing efficacy in the Type 2-low and Type 2-high asthma populations that IL-5 and IL-4/13 inhibitors cannot consistently address. The TSLP mechanism at the airway epithelial barrier acts upstream of both eosinophilic and non-eosinophilic inflammation, providing broad anti-inflammatory effects that translate into exacerbation reduction independent of the downstream inflammatory phenotype. The broad eligibility without biomarker testing requirement simplifies prescribing and creates a commercial positioning as the single biologic that can address the full severe asthma population without requiring eosinophil count, allergen sensitisation, or FeNO measurement thresholds.
Blood Eosinophil Count Above 150 to 300 Cells per Microlitre Biomarker for Anti-IL-5 Benralizumab and Mepolizumab Selection Has Established the Eosinophilic Phenotype Test That Guides the Biologic Selection for the Severe Asthma Patient Who Will Receive the Most Benefit.Sanofi and Regeneron's BOREAS and NOTUS Phase 3 trials demonstrated dupilumab reduction in moderate-to-severe COPD exacerbations by 30% in patients with blood eosinophil counts above 300 cells/μL, supporting FDA approval in this eosinophil-high subgroup and opening a disease affecting over 400 million people globally to biologic intervention for the first time. The COPD biologic opportunity is potentially larger than the severe asthma biologic market by prevalence, though the responding eosinophil-high subgroup represents approximately 20-30% of COPD patients rather than the entire population. Commercial launch uptake in COPD biologics will depend on pulmonologist prescribing behaviour in a specialty that has historically managed COPD with inhaled therapies and viewed biologics as relevant only in asthma.
ICS-Formoterol As-Needed Reliever Symbicort 64 Percent Exacerbation Reduction Versus Salbutamol in Mild Asthma SYGMA Has Established the Anti-Inflammatory Reliever Concept That GINA 2021 Adopted as the Preferred Step 1 Approach Addressing Airway Inflammation at the First Symptom.Adherence to maintenance inhaled corticosteroid therapy is below 50% in most real-world asthma populations, and the discrepancy between clinical trial efficacy of 40-60% exacerbation reduction and real-world effectiveness that typically falls below 30% is primarily attributable to inhaler non-adherence. Smart inhaler attachments from Propeller Health and Adherium collect inhaler actuation data that is transmitted to patient apps and prescriber dashboards, enabling pharmacist and nurse-led adherence interventions that have demonstrated 40-80% adherence improvement in pilot programmes. The commercial model for digital adherence solutions involves pharmaceutical partnerships where inhaler manufacturers like AstraZeneca, Boehringer Ingelheim, and GSK integrate electronic monitoring into the inhaler device to enable adherence-informed prescribing decisions.
For related market intelligence, see the Respiratory Drug Market.
8. Segmental Analysis
By drug class, the inhaled corticosteroid combination segment dominated the Asthma Market in 2025, as GSK's Trelegy and AstraZeneca's Symbicort anchored maintenance therapy across moderate and severe disease, generating the largest prescription volume in the indication.
By phenotype, the severe eosinophilic segment is projected to register the highest growth rate through 2034, as biologics including Sanofi and Regeneron's Dupixent and GSK's Nucala expand among patients with type-2 inflammation who remain uncontrolled on inhaled therapy and increasingly start biologics earlier.
9. Regional Analysis
Regional demand patterns across the Asthma Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Asthma Market in 2025, accounting for approximately 46% of global revenue, attributed to US premium pricing for asthma biologics including dupilumab, mepolizumab, benralizumab, and tezepelumab and the large severe asthma patient population. Moreover, biologic asthma adoption and triple inhaler prescribing are most advanced in the US. In addition, type 2 low biologic uptake with tezepelumab sustains demand. Regional dominance is due to this combination of pricing environment and biologic adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Asthma Market through 2034, driven by the large asthma patient population in China, Japan, and South Korea and expanding asthma biologic access through reimbursement. The region is also witnessing triple inhaler ICS-LABA-LAMA adoption growing. Moreover, severe asthma diagnosis and biologic prescribing are expanding. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Asthma Market was valued at USD 21.78 Bn in 2025 and is projected to reach USD 33.21 Bn by 2034, growing at a CAGR of 4.8% over the 2026–2034 forecast period.
The Asthma Market is projected to grow at a CAGR of 4.8% from 2026 to 2034.
North America dominated the Asthma Market in 2025, accounting for approximately 46% of global revenue, attributed to US premium pricing for asthma biologics including dupilumab, mepolizumab, benralizumab, and tezepelumab and the large severe asthma patient population.
The leading companies in the Asthma Market include GSK, AstraZeneca, Sanofi, Regeneron, Roche, Novartis, Teva Pharmaceutical, Verona Pharma, Mereo BioPharma, Amgen, Boehringer Ingelheim, Merck, Cipla, Sun Pharma, Lupin, Viatris, Vectura Group, Glenmark Pharmaceuticals.
Tezepelumab tslp blockade navigator 70 percent exacerbation reduction across all blood eosinophil count levels including less than 150 has established the first severe asthma biologic benefiting the full spectrum beyond the eosinophil-selected subgroup that anti-il-5 biologics require.
By drug class, the inhaled corticosteroid combination segment dominated the Asthma Market in 2025, as GSK's Trelegy and AstraZeneca's Symbicort anchored maintenance therapy across moderate and severe disease, generating the largest prescription volume in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.